Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: a needed bounce

September 9, 2020 8:10am

If and as it sustains

Pre-open indications: 1 BUY and 7 SELLs

The Biostage (BSTG) Chronicles … the deck hands are leaving a sinking ship, another director resigned; this time, the chair of the Audit Committee, effective immediately. The other audit committee member and director left five (5) months ago. Funny as the VP of Finance EXITED 8/24 <read more>

What I provide is an intelligence daily. RMi outlines the potential prelude to the daily dosage of facts and objectivity! Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!

My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!

Dow futures are UP +0.47% (+128 points), S&P futures are UP +0.70% (+23 points) and NASDAQ futures are UP +1.44% (+160 points)

U.S. stock futures rebounded on Wednesday as investors snapped up technology shares that were pummeled in the previous three sessions;

European stocks advanced hopefully ignoring the technology-led rout with the pan-European Stoxx 600 climbed +0.8% by mid-morning;

Asia-Pacific stocks declined with technology shares regionally seeing losses as the MSCI Asia ex-Japan index declined -1%.

Henry’omics:

The recent sell-off reflects an accumulation of investor worries centered on the performance of technology and growth stocks.

Interesting rumor and potential thesis of the decline, “Shares of Japanese conglomerate Softbank Group fell 2.87%. The stock has plunged more than 10% since its Friday close (Financial Times report identified the firm) as the “Nasdaq whale” that bought billions of dollars in technology company stock options over the past month.” <CNBC>

Tuesday night’s post: RegMed Investors’ (RMi) closing bell: “why, the beating? There is no pulse … It’s oversold, speculative and sentiment is in the toilet without news of any accomplishment i.e. complacent with profit taking being the extreme”

The Nasdaq closed DOWN -465.44 (-4.11%)
The IBB closed down -1.86% and XBI also closed down -1.35%
Sector volume was LOW with 4 of the 14-upside having higher than the 3-month average volume and the 3 of 19-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was up +0.71 points or +2.31% at 31.46
Tuesday’s percentage (%) of the 14-upside were +0.13% (ALNY) to +8.89% (BSTG) while the 19-downside ranges from -0.06% (VCEL) to -5.26% (ADRO);

Q3 so far:

September, 5 negative closes and 1 holiday
August, 10 positive closes and 11 negative closes
July -11 positive and 11 negative closes with 1 holiday

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed up +$0.12 to $1.47 following Friday’s close at $1.35, Thursday’s -$0.13 to $1.30 and last Wednesday’s +$0.03 to $1.48,

Analysts ask questions … and usually don’t get a response from this company. Wonder WHY the “EXODUS”?

Question #1 – WHY the IMMEDIATE resignation as a member of the board directors (BOD) and the LAST and ONLY member of the audit committee left (the other left in April) – four (4) directors remain – three (3) Chinese who are non-residents. Maybe they should update their website? SEC Form 8-K filed 9/9 – resignation was rendered on 9/3 – a little late in notification to SHARE HOLDERS (9/11) of a SERIOUS material FACT).

Question#2; WHO will sign the Q3 quarterly now that the VP of Finance is gone who recently took a “temporary leave of absence for personal reasons” effective 8/24?

Question#3; Are these issues related and WHAT and WHERE does RMS - the accounting firm STAND with NO substantiation from an audit board member or a principal accounting person?

SELL into any Strength:

AxoGen (AXGN) closed down -$0.16 to $11.44 following Friday’s $11.80 and has a negative -$0.16 or -1.41% aftermarket indication and a short ration of 4.81;

CRISPR Therapeutics (CRSP) closed down -$0.56 to $81.46 after Friday’s $82.02 and has a negative -$0.47 or -0.58% aftermarket indication having seen a high 9/1 at $93.42, a 52-week change of +77.53 and a short percentage (%) of float of 7.35;

Editas Medicine (EDIT) closed down -$1.22 to $29.25 after Friday’s $30.47 and a 52-week change of +19.35% with a short percentage (%) of float of 14.83%;

Intellia Therapeutics (NTLA) closed down -$0.65 to $17.47 after Friday’s $18.12 and has a negative -$0.17 or -0.97% after market indication, a 52-week change of +26.01% and a short percentage (%) of float of 26.11% (10.96 million shares);

Sage Therapeutics (SAGE) closed down -$0.63 to $51.03 after Friday’s $ and has a negative -$0.14 or -0.27% aftermarket indication with a short percentage (%) of float of 19.32%;

BUY:

Global Blood Therapeutics (GBT) closed down -$0.26 to $58.74 after Friday’s $ and has a positive +$0.90 or +1.15% aftermarket indication on news of entering into an exclusive agreement with Biopharma-Middle East and Africa (Biopharma-MEA) to distribute Oxbryta® (voxelotor) tablets in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, collectively known as the Gulf Cooperation Council (GCC) region. There are estimated to be more than 100,000 people age 12 years and older in this region living with sickle cell disease (SCD).

SELL into Strength

Fate Therapeutics (FATE) closed down -$0.70 to $30.41 and has a positive +$0.04 or +0.14% aftermarket indication, a 52-week change of +62.88% and a short percentage (%) of float of 19.86;

The BOTTOM LINE: sticking to last night’s (Tuesday’s) review; “Profit-taking and speculation surrounds individual stocks in “our’ universe of RegMed, cell and gene therapy equities.”

It’s oversold, speculative and sentiment is in the toilet without news of any accomplishment i.e. complacent with profit taking being the extreme

As the sessions of extremes widen, more stocks are infected.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.